NCT02841579 - Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 2, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

February 14, 2020

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

Osimertinib

The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose.

Trial Locations (7)

15706

MedSIR Investigative Site, A Coruña

28006

MedSIR Investigative Site, Madrid

29010

MedSIR Investigative Site, Málaga

46015

MedSIR Investigative Site, Valencia

48903

MedSIR Investigative Site, Bilbao

08026

MedSIR Investigative Site, Barcelona

08028

MedSIR Investigative Site, Barcelona